ÂÜÀòÂÒÂ×

Mr. Francisco Salva has over 20 years of experience in biotechnology finance, venture capital and operating roles. He is a Founder of Acerta Pharma BV and served as its Vice President of Operations, until the sale of 55% control to AstraZeneca for $4 billion. There, he was responsible for growth oriented activities including corporate finance, business development, human capital, legal and project management. Prior to Acerta, he served as Senior Director of Corporate Finance at Pharmacyclics, where he participated in the strategic turnaround of the company that reprioritized focus and efforts on ibrutinib.

Earlier in his career, Mr. Salva spent almost a decade in life sciences venture capital, starting his investment career at Patricof & Co, Ventures (now Apax Partners) before moving to lead investments at Invesco and CIBC Capital Partners. Over this period of his career, he invested in over 20 companies, leading to 9 exits that generated over $5 billion in total equity value.

Mr. Salva completed his MSc. degree at the London School of Economics and graduated magna cum laude from Brown University with an A.B. in Business Economics and an A.B. in Philosophy.